Attached you will find the charts with the expiration days for pens and vials for each brand of insulin.

The Alabama Medicaid Agency is making changes to payment for atovaquone oral suspension, and has updated its preferred drug list.

Effective January 1, 2015, the preferred short and intermediate acting insulin will be Novolin and Novolog for Commercial and Exchange Market formularies.

Humulin, Humalog, and Apidra will be non-preferred, and in most cases, will require a Prior Authorization (PA) or be excluded entirely from the Covered Person’s formulary.

To ensure a smooth transition for impacted Covered Persons, Participating Pharmacies are encouraged to assist their Covered Persons to get a new prescription from their Prescribing Provider.

Reminder: Starting January 1, 2015, Novolin, Novolog, Lantus and Levemir will be the insulin products with preferred brand status for Blue Cross and Blue Shield of Illinois, Blue Cross and Blue Shield of Montana, Blue Cross and Blue Shield of New Mexico, Blue Cross and Blue Shield of Oklahoma, and Blue Cross and Blue Shield of Texas Commercial formularies. (Novolin and Novolog will be the insulin products with preferred brand status for Exchange Affected Market formularies.)

Effective January 1, 2015, Novolin, Novolog, Lantus and Levemir will be the insulin products with preferred status for Commercial and Exchange Market formularies.  Please see the attachment below for further processing instructions.